List of Excipients in Branded Drug ISOPTO ATROPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	ISOPTO ATROPINE	atropine sulfate	0065-0303	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	ISOPTO ATROPINE	atropine sulfate	0065-0303	BORIC ACID
Alcon Laboratories Inc	ISOPTO ATROPINE	atropine sulfate	0065-0303	HYDROCHLORIC ACID

ISOPTO ATROPINE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 20, 2026

ISOPTO ATROPINE is an atropine sulfate ophthalmic solution marketed by Alcon for cycloplegia and mydriasis. Its commercial formulation is relatively simple: atropine sulfate in an aqueous borate-buffered vehicle, with benzalkonium chloride used as a preservative in the labeled product. The principal opportunity is not a conventional composition patent around the legacy product. It is development of preservative-free, low-dose, sustained-release, or device-enabled atropine products that improve tolerability, dosing adherence, and pediatric use.

The core commercial risks are generic substitution, low barriers to manufacturing the basic solution, and limited differentiation in conventional atropine sulfate drops. The strongest opportunities are in pediatric myopia control, preservative-free multidose delivery, reduced- exposure formulations, and delivery systems that reduce drop frequency.

What is ISOPTO ATROPINE and how is it formulated?

ISOPTO ATROPINE contains atropine sulfate, an anticholinergic drug used topically in the eye. The product is supplied as ophthalmic solution in 0.5%, 1%, and 2% strengths, according to U.S. product labeling. The labeled inactive ingredients include boric acid, sodium borate, benzalkonium chloride, and purified water. Hydrochloric acid and sodium hydroxide may be used for pH adjustment. [1]

Attribute	ISOPTO ATROPINE profile
Brand	ISOPTO ATROPINE
Marketing company	Alcon Laboratories, Inc.
Active ingredient	Atropine sulfate
Dosage form	Sterile ophthalmic solution
U.S. strengths	0.5%, 1%, and 2%
Primary uses	Cycloplegia and mydriasis
Preservative	Benzalkonium chloride in the labeled formulation
Vehicle	Aqueous borate-buffered system
Administration	Topical ocular drops
Regulatory pathway	Prescription ophthalmic drug
Reference-product status	Legacy FDA-approved product
Main competitive threat	Generic atropine sulfate ophthalmic solution

The formulation has conventional characteristics for an aqueous ophthalmic product. Boric acid and sodium borate provide buffering and contribute to osmotic control. Benzalkonium chloride supports multidose-container microbiological preservation but can create tolerability and ocular-surface concerns, particularly with repeated administration.

What excipients are used in ISOPTO ATROPINE?

The principal excipients are boric acid, sodium borate, benzalkonium chloride, and purified water. The formulation may also use hydrochloric acid or sodium hydroxide to adjust pH during manufacture. [1]

Functional role of each excipient

Excipient	Primary formulation function	Commercial relevance
Boric acid	Buffering and tonicity contribution	Low-cost, established ophthalmic excipient
Sodium borate	Buffering and pH control	Supports atropine sulfate solution stability
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but creates ocular-surface exposure
Purified water	Vehicle	Standard aqueous ophthalmic medium
Hydrochloric acid or sodium hydroxide	pH adjustment	Process-control excipients rather than primary differentiators

The current excipient system is unlikely to provide meaningful standalone product differentiation. Most components are well-established in ophthalmic products and are available from multiple qualified suppliers. A company seeking market protection would need to claim a specific concentration range, preservative-reduction strategy, delivery system, stability profile, or clinically relevant performance benefit.

What formulation patents protect ISOPTO ATROPINE?

No material, currently enforceable U.S. patent estate should be assumed for the basic ISOPTO ATROPINE composition without a current patent-database review. Atropine ophthalmic products have been marketed for decades, and the core combination of atropine sulfate, borate buffer, water, and benzalkonium chloride is unlikely to support broad new patent protection.

The relevant intellectual-property opportunity is more likely to arise from a new product architecture rather than from the legacy formula.

Potentially protectable formulation features

Innovation area	Potential claim subject	Relative patent value
Preservative-free solution	Unit-dose or sterile multidose atropine formulation	Moderate
Low-dose atropine	Concentrations optimized for myopia control	Moderate to high
Sustained release	Ocular insert, hydrogel, depot, or particulate delivery	High
Device delivery	Metered-dose or contamination-resistant dispenser	Moderate to high
Improved tolerability	Reduced benzalkonium chloride or alternative preservative system	Moderate
Stability enhancement	Specific pH, buffer, chelator, or packaging combination	Moderate
Combination therapy	Atropine with another ophthalmic active	High if clinically differentiated
Manufacturing process	Sterilization, filling, or crystallization controls	Usually narrower

A patent directed only to substituting one conventional buffer for another would face substantial obviousness risk. A stronger patent position would link the excipient system to a measurable technical result, such as improved atropine stability, reduced degradation, lower ocular-surface toxicity, longer in-use stability, or reduced dosing frequency.

When does ISOPTO ATROPINE lose exclusivity?

ISOPTO ATROPINE is a legacy product and should be treated as post-exclusivity. FDA approval of the reference product does not create a current market monopoly comparable to a recently approved drug. The basic atropine sulfate ophthalmic solution is vulnerable to generic competition through abbreviated new drug applications.

FDA’s Orange Book identifies approved drug products and any applicable listed patents or exclusivity information. A current Orange Book review should be used to confirm the active listing, patent entries, and reference-product status for the specific strength and presentation. [2]

Exclusivity assessment

Exclusivity category	Assessment
New chemical entity exclusivity	Expired or inapplicable
Orphan-drug exclusivity	Not applicable to the conventional product
Pediatric exclusivity	No current commercial barrier should be assumed
New clinical investigation exclusivity	Not associated with the legacy formulation
Patent exclusivity	No broad current protection should be assumed for the basic solution
Regulatory competition	Generic ophthalmic atropine products are the principal route

The practical result is that commercial value depends on manufacturing efficiency, distribution, brand recognition, clinical positioning, and formulation differentiation rather than on legacy exclusivity.

What is the FDA regulatory status of ISOPTO ATROPINE?

ISOPTO ATROPINE is an FDA-approved prescription ophthalmic product containing atropine sulfate. The product is regulated as a sterile ophthalmic solution. Its core indications are cycloplegia and mydriasis. [1]

A new product using the same active ingredient may use different regulatory pathways depending on its design:

Product concept	Likely regulatory route
Same-strength conventional solution	ANDA, if therapeutic equivalence can be established
Preservative-free solution	ANDA or 505(b)(2), depending on formulation and reference-product relationship
New low-dose product for myopia control	505(b)(2) or NDA strategy
Sustained-release ocular insert	505(b)(2) or NDA
Combination product	NDA or 505(b)(2), depending on precedent and data
New delivery device with same solution	Combination-product review may apply

The regulatory burden rises as the product departs from a conventional aqueous drop. A preservative-free formulation may still require ophthalmic quality, sterility, container-closure, extractables and leachables, and stability data. Sustained-release systems would require additional pharmacokinetic, local-tolerance, dose-control, and device-performance evidence.

What formulation opportunities exist for atropine ophthalmic products?

Preservative-free atropine

Preservative-free atropine is the clearest excipient-driven opportunity. Benzalkonium chloride is effective and familiar, but repeated ocular exposure can contribute to epithelial toxicity, tear-film disruption, and discomfort. These concerns are commercially relevant in pediatric patients and in patients receiving chronic therapy.

Possible formats include:

• Unit-dose vials
• Blow-fill-seal ampoules
• Preservative-free multidose containers
• One-way valve dispensers
• Filtered or airless delivery systems
• Metered-dose ophthalmic pumps

A preservative-free product can command a price premium if it demonstrates better tolerability, longer treatment persistence, or a clear pediatric-use advantage. The weakness is packaging cost and the need to control microbial contamination without benzalkonium chloride.

Low-dose atropine for myopia control

Low-dose atropine, commonly discussed at concentrations below the 0.1% to 1% range, is used or studied for pediatric myopia control in several markets. These concentrations differ materially from ISOPTO ATROPINE’s labeled 0.5%, 1%, and 2% strengths.

Low-dose products create several formulation challenges:

• Accurate delivery at very low drug concentrations
• Uniformity across the shelf life
• Control of adsorption to containers and closures
• Pediatric tolerability
• Minimization of photophobia and near-vision effects
• Stability after opening
• Reliable compounding or commercial manufacturing

The strongest commercial product would combine low-dose atropine with a validated, stable, ready-to-use presentation. A pharmacy-compounded product may meet immediate demand but generally offers weaker manufacturing consistency, packaging control, and intellectual-property protection than an approved commercial product.

Reduced-preservative formulations

A formulation with lower benzalkonium chloride exposure could occupy a middle position between a conventional preserved drop and a fully preservative-free product. Potential strategies include:

• Lower preservative concentration validated for multidose use
• Alternative preservatives
• Preservative systems activated only during dispensing
• Container systems that prevent microbial ingress
• Shorter in-use periods with preservative-free packaging

Any alternative preservative must be assessed for ocular tolerance, antimicrobial effectiveness, compatibility with atropine sulfate, and regulatory acceptability. FDA’s Inactive Ingredient Database can help identify prior ophthalmic use, but database presence does not establish approval for a particular concentration or dosage form. [3]

Sustained-release delivery

Sustained-release delivery is the highest-value technical opportunity. It can reduce dosing frequency and improve adherence, particularly where atropine causes dose-related photophobia or blurred near vision.

Potential platforms include:

• Ocular inserts
• Bioadhesive gels
• In situ gelling systems
• Nanoparticles or microparticles
• Contact-lens delivery
• Punctal plugs
• Subconjunctival or intracanalicular depots

The patent value would depend on release kinetics, residence time, local tolerability, manufacturing reproducibility, and clinical outcomes. The main risk is that prolonged exposure may increase adverse effects even if peak exposure falls.

What manufacturing and excipient barriers affect commercial entry?

The basic aqueous solution has relatively low technical entry barriers. The commercial process generally requires compounding, sterile filtration or validated sterilization, aseptic filling, container-closure integrity, and microbiological quality control.

Manufacturing considerations

Manufacturing issue	Impact on entrant
Atropine sulfate assay	Requires tight potency control across low and high strengths
pH and osmolality	Affect comfort, stability, and ocular tolerability
Sterility assurance	Central requirement for all ophthalmic products
Preservative effectiveness	Required for preserved multidose presentations
Container interaction	Particularly important at low atropine concentrations
Light protection	May be relevant to active and formulation stability
In-use stability	Critical for multidose products
Fill-volume accuracy	Important for pediatric and low-dose products
Extractables and leachables	Increases with complex packaging and devices

The most defensible manufacturing IP may relate to a low-dose formulation, a specific filling process, a device-integrated container, or stability under defined storage conditions. Process patents can be commercially useful but are often easier to design around than composition or device claims.

Which companies are challenging or competing with ISOPTO ATROPINE?

Competition comes from generic atropine sulfate ophthalmic products, compounded low-dose atropine, and branded or pipeline products designed for myopia control. The conventional generic market is typically price-sensitive and may contain several approved suppliers.

The competitive landscape divides into four groups:

1. Generic manufacturers selling conventional atropine sulfate ophthalmic solution.
2. Compounding pharmacies supplying low-dose atropine, particularly where commercial low-dose products are unavailable.
3. Ophthalmic drug-delivery companies developing sustained-release systems.
4. Pediatric eye-care companies commercializing myopia-control products, including atropine-based and non-atropine approaches.

For a new entrant, the most difficult segment to defend is the standard 0.5%, 1%, or 2% preserved solution. Differentiation is stronger in preservative-free packaging, low-dose pediatric therapy, controlled delivery, and clinically demonstrated tolerability.

What paragraph IV challenges and litigation risks exist?

A conventional generic applicant may use an ANDA pathway and challenge any listed patents through a Paragraph IV certification if the reference product has relevant Orange Book patents. Because ISOPTO ATROPINE is a legacy product, the principal risk is ordinary generic substitution rather than a high-value patent litigation campaign.

A new branded formulation could generate Paragraph IV litigation if it receives Orange Book-listed patents covering:

• A specific low-dose concentration
• A preservative-free composition
• A delivery device
• A sustained-release system
• A method of treating myopia
• A stability-enhancing excipient combination

Method-of-use patents may be more relevant than composition patents for low-dose atropine used in myopia control. Their enforceability depends on claim scope, labeling, induced infringement, carve-out feasibility, and the actual prescribing market. FDA approval of a carved-out label does not eliminate all commercial exposure where off-label use is common.

No major settlement agreement should be attributed to ISOPTO ATROPINE without a case-specific review of court dockets, FDA submissions, and Orange Book listings. The product’s primary competitive exposure remains generic entry and substitution.

How does ISOPTO ATROPINE compare with a new preservative-free atropine product?

Category	ISOPTO ATROPINE	Preservative-free or low-dose entrant
Active ingredient	Atropine sulfate	Usually atropine sulfate
Conventional strengths	0.5%, 1%, 2%	Often lower concentrations for chronic use
Preservative	Benzalkonium chloride	None or alternative system
Dosing	Standard topical drop	May use metered or sustained delivery
Pediatric suitability	Limited by concentration and preservative exposure	Potentially stronger
Manufacturing complexity	Low to moderate	Moderate to high
Patent potential	Weak for legacy composition	Stronger for device, concentration, and delivery
Price competition	High	Lower if clinically differentiated
Regulatory burden	Established	Increases with formulation novelty
Commercial moat	Brand and distribution	Clinical benefit, packaging, and IP

What revenue exposure does generic entry create?

The revenue exposure is concentrated in conventional atropine sulfate ophthalmic solution, where price erosion can occur rapidly after generic entry. The exact impact depends on prescription volume, payer substitution, channel mix, and the availability of authorized or competing generics.

A simplified commercial scenario is:

Scenario	Commercial effect
Generic entry into standard strengths	Rapid price and share pressure
Multiple generic entrants	Greater substitution and margin erosion
Preservative-free line extension	Potential premium pricing
Low-dose myopia product	New market, but clinical and regulatory investment required
Sustained-release product	Higher price potential and stronger differentiation
Device-only improvement	Moderate premium if adherence benefit is demonstrated

The legacy product’s revenue is most defensible where prescribers value branded supply reliability, specific packaging, or established distribution. Those advantages are weaker in formularies that automatically substitute generic ophthalmic products.

How strong is the patent estate for ISOPTO ATROPINE?

The patent estate around the legacy product should be rated weak for the basic formulation and potentially strong only for future differentiated products.

Patent subject	Expected strength
Atropine sulfate ophthalmic solution generally	Weak
Boric acid and sodium borate vehicle	Weak
Benzalkonium chloride preservation	Weak
Specific low-dose formulation	Moderate
Preservative-free multidose system	Moderate to strong
Sustained-release delivery	Stronger, if clinically validated
Metered-dose device	Moderate
Method of treating pediatric myopia	Moderate, subject to claim and litigation risk
Manufacturing process	Narrow to moderate

Patent strength will depend on claim breadth, prior art, enablement, written description, obviousness, freedom to operate, and whether the claims cover commercially necessary product characteristics. The highest-value portfolio would combine composition, device, method-of-use, and manufacturing claims.

What licensing opportunities exist for atropine formulations?

Licensing opportunities are more likely to involve delivery technology than the ISOPTO ATROPINE brand itself. Potential licensors include:

• Preservative-free ophthalmic container manufacturers
• Metered-dose dispenser companies
• Ocular inserts and depot-delivery developers
• Low-dose atropine developers
• Pediatric ophthalmology companies
• Contract manufacturers with sterile ophthalmic capacity

A license should be evaluated against four commercial questions: whether the technology reduces dosing burden, whether it improves tolerability, whether it has patent coverage in the target markets, and whether the manufacturing process is scalable.

An exclusive license covering only a conventional atropine solution would have limited value. A field-limited license covering pediatric myopia control, a defined delivery platform, or a preservative-free multidose system would have greater strategic value.

What geographic markets offer the best opportunities?

The United States offers the largest opportunity for an FDA-approved low-dose or preservative-free product, but it also has high regulatory and litigation costs. Europe and Asia may offer strong demand in pediatric myopia control, with country-specific regulatory and reimbursement requirements.

Geographic considerations

Market	Opportunity	Main barrier
United States	Premium pediatric and preservative-free products	FDA approval, reimbursement, generic substitution
European Union	Myopia-control demand and preservative-free positioning	Centralized or national regulatory pathways
China	Large pediatric myopia population	Local registration, pricing, local competition
Japan	High ophthalmic quality expectations	PMDA requirements and market access
Southeast Asia	Growing demand for myopia products	Price sensitivity and distribution
Latin America	Established atropine use in some markets	Regulatory fragmentation and procurement pressure

Territorial patent protection should focus on countries where low-dose atropine, controlled delivery, or preservative-free packaging can support a meaningful price premium. Broad global filing for a conventional solution is unlikely to provide an attractive return.

Key Takeaways

• ISOPTO ATROPINE is a legacy atropine sulfate ophthalmic solution in 0.5%, 1%, and 2% strengths.
• Its labeled excipients include boric acid, sodium borate, benzalkonium chloride, purified water, and pH-adjustment agents.
• The basic formulation has limited apparent patent value and is exposed to generic competition.
• Preservative-free delivery is the most accessible excipient-led opportunity.
• Low-dose atropine for pediatric myopia control offers a larger market opportunity but requires stronger dose-uniformity, stability, and clinical positioning.
• Sustained-release systems and metered-dose devices offer the strongest potential patent differentiation.
• Method-of-use patents may be important for myopia-control products, while device and formulation claims can provide broader commercial protection.
• The best licensing targets are delivery platforms, sterile ophthalmic manufacturing systems, and clinically validated low-dose formulations.
• Conventional 0.5%, 1%, and 2% solutions are likely to face high price pressure after generic substitution.

FAQs About ISOPTO ATROPINE Excipient and Commercial Strategy

Can benzalkonium chloride be removed from ISOPTO ATROPINE?

Yes, but removal requires a new preservative-free presentation or a validated alternative microbial-control system. The product would need supporting sterility, container-closure, stability, and in-use data.

Is low-dose atropine the same product as ISOPTO ATROPINE?

No. ISOPTO ATROPINE is labeled in 0.5%, 1%, and 2% strengths. Low-dose atropine products used for myopia control generally use lower concentrations and may require a different regulatory and commercial strategy.

Which excipient is most important for differentiating an atropine product?

The most commercially important change is often the removal or reduction of benzalkonium chloride. Buffer selection alone is unlikely to create durable differentiation unless it produces a documented stability or tolerability advantage.

Can a new atropine product receive Orange Book-listed patents?

Yes. A new FDA-approved product may receive listed patents covering its formulation, device, method of use, or manufacturing process if the patents satisfy FDA listing requirements. Listing does not guarantee validity or enforceability.

Is a sustained-release atropine product likely to be more valuable than a conventional eye drop?

Yes, if it reduces dosing frequency and improves adherence without increasing photophobia, blurred vision, or other local adverse effects. Its value depends on clinical evidence, manufacturability, and enforceable patent claims.

References

1. U.S. Food and Drug Administration. (n.d.). ISOPTO ATROPINE (atropine sulfate) ophthalmic solution prescribing information. Alcon Laboratories, Inc.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2025). Inactive Ingredient Database.
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: Quality considerations for topical ophthalmic drug products.